KEQU

Shares of Kewaunee Scientific Corporation KEQU have declined 17.5% since reporting results for the third quarter of fiscal 2026, underperforming the S&P 500 index’s 2.2% fall over the same period. Over the past month, the stock has lost 15.7% compared with a 3.4% dip in the broader index, indicating a sharper negative market reaction to the company’s recent performance. Kewaunee reported mixed financial results for the fiscal third quarter ended Jan. 31, 2026. Net sales rose 3.3% year over year to $69.4 million from $67.2 million, reflecting modest top-line growth. However, profitability weakened significantly. Net earnings attributable to the company dropped roughly 49% to $0.7 million from $1.35 million in the prior-year period. Diluted earnings per share fell to 23 cents from 45 cents a year ago. While pre-tax earnings increased 25.8% to $1.6 million, the decline in net income suggests the impacts of higher taxes and non-controlling interests during the quarter. Kewaunee Scientific Corporation price-consensus-eps-surprise-chart | Kewaunee Scientific Corporation Quote Performance across segments was uneven. The domestic segment, which remains the largest contributor, reported sales of $51 million, down 2% year over year. Segment net earnings declined to $2.29 million from $2.88 million, with EBITDA also falling to $4.1 million from $5.2 million. The decline was attributed to lower manufacturing volumes, particularly in the laboratory construction portion of the business. In contrast, the international segment delivered strong growth. Sales increased 21.4% to $18.4 million, while net earnings surged to $1.26 million from $0.48 million. EBITDA nearly tripled to $2 million, driven primarily by higher billings in the Indian market. Order backlog, an important indicator of future revenues, stood at $183.2 million at the quarter-end, down from $221.6 million a year earlier and $214.6 million at the start of the fiscal year, signaling some softening in demand visibility. Management highlighted several external and internal factors shaping the quarterly performance. CEO Thomas D. Hull III noted that the third quarter is typically the company’s weakest due to seasonal effects, including holiday-related slowdowns and reduced construction activity during winter months. These cyclical factors were compounded by geopolitical and economic uncertainty, as well as volatil...

STATESVILLE, N.C., March 11, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its third quarter ended January 31, 2026. Fiscal Year 2026 Third Quarter Results: Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITDA1 for the quarter was $3,795,000 compared to $3,734,000 for the prior year quarter. Diluted earnings per share were $0.23 compared to diluted earnings per share of $0.45 in the prior year quarter. The Company's order backlog was $183.2 million on January 31, 2026, as compared to $221.6 million on January 31, 2025, and $214.6 million on April 30, 2025. Domestic Segment - Domestic sales for the quarter were $50,953,000, a decrease of 2.0% from sales of $51,976,000 in the prior year quarter. Domestic segment net earnings were $2,290,000 compared to $2,876,000 in the prior year quarter. Domestic segment EBITDA was $4,096,000 compared to $5,249,000 for the prior year quarter. Segment profitability was impacted during the period by lower manufacturing volumes across the laboratory construction portion of the business. International Segment - International sales for the quarter were $18,446,000, an increase of 21.4% from sales of $15,191,000 in the prior year quarter. International segment net earnings were $1,256,000 compared to $476,000 in the prior year quarter. International segment EBITDA was $1,963,000 compared to $760,000 for the prior year quarter. International profitability increased when compared to the prior year period due to higher billings, principally in the Indian market. Corporate Segment – Corporate segment pre-tax net loss was $3,059,000 for the quarter, as compared to a pre-tax net loss of $3,025,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,264,000) compared to corporate segment EBITDA of ($2,275,000) for the prior year quarter. Corporate segment EBITDA remained relatively flat as the Company continues to make strategic investments in people, processes, and technology to further build out its Corporate platform and support continued...

Kewaunee Scientific (KEQU) reported fiscal Q3 adjusted earnings late Wednesday of $0.28 per diluted

STATESVILLE, N.C., Feb. 25, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its third quarter fiscal year 2026 financial results on Wednesday, March 11, 2026 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China. Learn more at the companies' websites, located at http://www.kewaunee.com and http://www.nuaire.com/. This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intende...

Shares of Kewaunee Scientific Corporation KEQU have declined 1.3% since reporting results for the second quarter of fiscal 2026. This compares with the S&P 500 index’s 0.7% return over the same time frame. Over the past month, the stock has declined 4.5% against the S&P 500’s 3% growth. For the quarter ended Oct. 31, 2025, Kewaunee reported net sales of $70.1 million, representing a 46.8% increase from $47.8 million in the year-ago period. Despite the sharp rise in revenues, profitability declined year over year. Net earnings attributable to Kewaunee were $2.4 million, down from $3 million a year earlier, while diluted earnings per share fell to 82 cents from $1.01. Pre-tax earnings declined 12.2% year over year to $3.5 million. EBITDA, a non-GAAP measure, increased to $5.8 million from $4.9 million in the prior-year quarter, reflecting improved operating scale and contributions from acquisitions despite margin pressure. Kewaunee Scientific Corporation price-consensus-eps-surprise-chart | Kewaunee Scientific Corporation Quote Order backlog stood at $192.9 million as of Oct. 31, 2025, compared with $184.4 million a year earlier, though it declined sequentially from $214.6 million at the end of fiscal 2025. The backlog remains near historically high levels, particularly within the Domestic segment. On the balance sheet, total cash on hand was $13.7 million, down from $17.2 million at April 30, 2025, while working capital improved year over year to $67.8 million from $60 million. Long-term debt declined to $58.2 million from $60.7 million at the fiscal year-end, and the company’s debt-to-equity ratio improved to 0.88-to-1 from 0.99-to-1, signaling gradual balance-sheet strengthening in the quarter. Segmental performance was mixed. Domestic sales increased 51.7% year over year to $55.2 million, driven partly by the inclusion of Nu Aire, Inc., which delivered strong quarterly results. However, the domestic segment’s net earnings declined to $3.6 million from $4.5 million a year earlier due to lower manufacturing volumes in the laboratory construction portion of the business. International sales rose 31% year over year to $14.9 million, supported by the continued delivery of large projects booked in prior periods. International segment net earnings improved to $0.6 million from $0.4 million, and segment EBITDA increased accordingly. Management emphasized that proj...

Kewaunee Scientific (KEQU) reported fiscal Q2 earnings late Wednesday of $0.82 per diluted share, do

STATESVILLE, N.C., Dec. 10, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its second quarter ended October 31, 2025. Fiscal Year 2026 Second Quarter Results: Sales during the second quarter of fiscal year 2026 were $70,096,000, an increase of 46.8% compared to sales of $47,764,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,453,000 compared to $3,931,000 for the prior year quarter, a decrease of 12.2%. Net earnings were $2,445,000 compared to net earnings of $3,008,000 for the prior year quarter. EBITDA1 for the quarter was $5,790,000 compared to $4,883,000 for the prior year quarter. Diluted earnings per share were $0.82 compared to diluted earnings per share of $1.01 in the prior year quarter. The Company's order backlog was $192.9 million on October 31, 2025, as compared to $184.4 million on October 31, 2024, and $214.6 million on April 30, 2025. Domestic Segment - Domestic sales for the quarter were $55,224,000, an increase of 51.7% from sales of $36,409,000 in the prior year quarter. Domestic segment net earnings were $3,597,000 compared to $4,524,000 in the prior year quarter. Domestic segment EBITDA was $6,712,000 compared to $6,838,000 for the prior year quarter. Segment profitability was impacted during the period by lower manufacturing volumes across the laboratory construction portion of the business, offset by the addition of Nu Aire, Inc. ("Nu Aire"), who had a strong quarter. International Segment - International sales for the quarter were $14,872,000, an increase of 31.0% from sales of $11,355,000 in the prior year quarter. International segment net earnings were $641,000 compared to $356,000 in the prior year quarter. International segment EBITDA was $860,000 compared to $592,000 for the prior year quarter. International sales increased when compared to the prior year period due to the continued delivery of large projects that were booked in prior periods, a trend that continues from the Company's first quarter fiscal year 2026 results. Corporate Segment – Corporate segment pre-tax net loss was $2,515,000 for the quarter, as compared to a pre-tax net loss of $2,444,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($1,782,000) compared to corporate segment EBITDA of ($2,547,000) for the prior year quarter. Corporate segment EBITDA im...

STATESVILLE, N.C., Nov. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China. Learn more at the companies' websites, located at http://www.kewaunee.com and http://www.nuaire.com/. This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are int...

Shares of Kewaunee Scientific Corporation KEQU have declined 19.7% since reporting first-quarter fiscal 2026 results. This compares with the S&P 500 index’s 0.4% rise over the same period. Over the past month, the stock has fallen 23.8%, while the S&P 500 has advanced 1.9%. The performance highlights a sharp underperformance relative to the broader market despite a set of results that, on balance, showed strong top and bottom-line growth. The company reported first-quarter fiscal 2026 sales of $71.1 million, a 46.9% increase from $48.4 million in the prior-year quarter. Net earnings rose 41.1% to $3.1 million from $2.2 million a year ago. Diluted earnings per share grew 40.5% to $1.04 from 74 cents in the same quarter last year. EBITDA nearly doubled to $6.3 million from $3.3 million in the prior-year period. This robust performance was underpinned by growth across both domestic and international segments, as well as contributions from the recently acquired Nu Aire business. Kewaunee Scientific Corporation price-consensus-eps-surprise-chart | Kewaunee Scientific Corporation Quote The company’s order backlog stood at $205 million as of July 31, 2025, up from $159.4 million a year earlier, though slightly down from $214.6 million at the end of April 2025. Domestic sales soared 53% to $54.4 million, while international sales advanced 30.2% to $16.8 million. The domestic segment delivered net earnings of $4.7 million compared with $2.9 million a year ago, while international earnings improved to $0.6 million from $0.5 million. Segment EBITDA also grew strongly — $7.6 million for domestic and $1.1 million for international, reflecting improved productivity and higher billings. Working capital rose to $66.7 million from $56 million a year earlier, while total cash on hand increased to $20.4 million at quarter-end from $17.2 million in April 2025. Debt metrics showed improvement. Short-term debt declined to $4.3 million from $4.8 million in April, and long-term debt eased to $60.3 million from $60.7 million. The debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1 three months earlier. CEO Thomas D. Hull III acknowledged that the strong quarterly results were achieved against a backdrop of challenging market conditions, including shifting government policies, evolving tariffs and geopolitical uncertainties. He cautioned that the company expects uneven quarterl...

Revenue: US$71.1m (up 47% from 1Q 2025). Net income: US$3.09m (up 41% from 1Q 2025). Profit margin: 4.3% (down from 4.5% in 1Q 2025). The decrease in margin was driven by higher expenses. EPS: US$1.09 (up from US$0.77 in 1Q 2025). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Kewaunee Scientific shares are down 21% from a week ago. You should learn about the 4 warning signs we've spotted with Kewaunee Scientific. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

STATESVILLE, N.C., Sept. 10, 2025 /PRNewswire/ -- PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first quarter ended July 31, 2025. Fiscal Year 2026 First Quarter Results: Sales during the first quarter of fiscal year 2026 were $71,104,000, an increase of 46.9% compared to sales of $48,393,000 from the prior year's first quarter. Pre-tax earnings for the quarter were $3,920,000 compared to $2,430,000 for the prior year quarter, an increase of 61.3%. Net earnings were $3,093,000 compared to net earnings of $2,193,000 for the prior year quarter. EBITDA1 for the quarter was $6,320,000 compared to $3,325,000 for the prior year quarter. Diluted earnings per share were $1.04 compared to diluted earnings per share of $0.74 in the prior year quarter. The Company's order backlog was $205.0 million on July 31, 2025, as compared to $159.4 million on July 31, 2024, and $214.6 million on April 30, 2025. Domestic Segment - Domestic sales for the quarter were $54,352,000, an increase of 53.0% from sales of $35,523,000 in the prior year quarter. Domestic segment net earnings were $4,722,000 compared to $2,871,000 in the prior year quarter. Domestic segment EBITDA was $7,576,000 compared to $4,738,000 for the prior year quarter. The increase in Domestic sales and earnings was driven by the incorporation of Nu Aire's results, steady manufacturing volumes, improved productivity, and cost management actions. International Segment - International sales for the quarter were $16,752,000, an increase of 30.2% from sales of $12,870,000 in the prior year quarter. International segment net earnings were $643,000 compared to $463,000 in the prior year quarter. International segment EBITDA was $1,055,000 compared to $696,000 for the prior year quarter. The impact of customer site delays experienced during most of the prior fiscal year began decreasing during the fourth quarter of fiscal year 2025, resulting in increased deliveries and billings for the first quarter of fiscal year 2026 compared to the comparable prior year period. Corporate Segment – Corporate segment pre-tax net loss was $3,058,000 for the quarter, as compared to a pre-tax net loss of $1,992,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,311,000) compared to corporate segment EBITDA of ($2,109,000) for the prior year quarter. Corporate segment...

Kewaunee Scientific (KEQU) reported fiscal Q1 adjusted earnings late Wednesday of $1.10 per diluted